Menu
SOPHiA GENETICS is thrilled to return for ACMG 2025! Visit us at booth #322 to learn more about our SOPHiA DDM™ and Alamut™ Visual Plus platforms for rare and inherited diseases.
Exhibit Theater
Friday, March 21.
11:20 am – 11:50 am.
Theatre 2
Streamlining genomic complexity with SOPHiA DDM™ and Alamut™ Visual Plus
Elexandra Barboza Arguedas, National Children’s Hospital, CCSS, University of Costa Rica, University of Medical Sciences.
Sevana Yaghoubian, MSc - Senior Director of Product Management, SOPHiA GENETICS.
Discover how our AI-powered platform is transforming germline variant analysis and interpretation, enabling scientists to uncover actionable insights with unmatched accuracy and efficiency. This session showcases the innovative features of the new-generation SOPHiA DDM™ Platform and the latest advancements in Alamut™ Visual Plus, purpose-built to optimize workflows and drive impactful outcomes.
Through the perspective of a medical laboratory scientist, discover SOPHiA DDM™’s capabilities for hereditary cancer and exome applications. Experience how its dedicated features set new standards in the assessment of even the most challenging variants and get an exclusive look at exciting functionalities debuting this year.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
